ONO-4686 is a monoclonal antibody commercialized by Ono Pharmaceutical, with a leading Phase II program in Oropharyngeal Cancer. According to Globaldata, it is involved in 4 clinical trials, of which 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of ONO-4686’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ONO-4686 is expected to reach an annual total of $24 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
BMS-986207 is under development for the treatment of advanced solid tumors and relapsed refractory multiple myeloma, epithelial ovarian cancer, primary peritoneal, fallopian tube cancer and endometrial cancer, head and neck squamous cell carcinoma including oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, paranasal sinus, nasopharyngeal cancers. The drug candidate is administered through parenteral route as an injection. It acts by targeting TIGIT protein.
It was also under development for the treatment of non-small cell lung cancer and squamous non-small cell lung cancer.
Ono Pharmaceutical Overview
Ono Pharmaceutical focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusions. Ono Pharmaceutical has three manufacturing facilities; Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY361,361 million for the fiscal year ended March 2022 (FY2022), an increase of 16.8% over FY2021. In FY2022, the company’s operating margin was 28.6%, compared to an operating margin of 31.8% in FY2021. In FY2022, the company recorded a net margin of 22.3%, compared to a net margin of 24.4% in FY2021. The company reported revenues of JPY122,319 million for the third quarter ended December 2022, an increase of 11.2% over the previous quarter.
For a complete picture of ONO-4686’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.